HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PF-00489791

a phosphodiesterase type 5 inhibitor

Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - PF-00489791: 3
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - PF-00489791: 3
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - PF-00489791: 3

Experts

1.	Clerin, Valerie: 1 article (11/2016)
2.	Diamond, Susan: 1 article (11/2016)
3.	El Nahas, Meguid: 1 article (11/2016)
4.	Gale, Jeremy: 1 article (11/2016)
5.	Grover-Páez, Fernando: 1 article (11/2016)
6.	Le, Vu: 1 article (11/2016)
7.	Perros-Huguet, Christelle: 1 article (11/2016)
8.	Rolph, Timothy: 1 article (11/2016)
9.	Scheele, Wim: 1 article (11/2016)
10.	Tamimi, Nihad: 1 article (11/2016)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/2009 - "In conclusion, PF-00489791 causes a clinically meaningful and sustained BP lowering in patients with hypertension. " 06/01/2009 - "In this study, a novel long-acting phosphodiesterase 5 inhibitor, PF-00489791, was evaluated in 133 patients with mild to moderate hypertension, randomized into 1 of 4 groups: placebo, 4 mg, 10 mg, and 20 mg titrated after 14 days of dosing to 40 mg. Study medication was administered once daily for 28 days. "
2.	Diabetic Nephropathies (Diabetic Nephropathy) 09/01/2015 - "A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin-angiotensin system blockade."
3.	Type 2 Diabetes Mellitus (MODY) 11/01/2016 - "To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy. "
4.	Albuminuria 09/01/2015 - "A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin-angiotensin system blockade."

Related Drugs and Biologics

1.	Phosphodiesterase 5 Inhibitors
2.	Angiotensin Receptor Antagonists
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1.	Therapeutics